Review
Version 5
Preserved in Portico This version is not peer-reviewed
A New Paradigm in Cancer Treatment: Identifying and Targeting Clonal Mutations
Version 1
: Received: 21 August 2023 / Approved: 21 August 2023 / Online: 22 August 2023 (07:58:07 CEST)
Version 2 : Received: 5 September 2023 / Approved: 6 September 2023 / Online: 7 September 2023 (02:54:00 CEST)
Version 3 : Received: 31 December 2023 / Approved: 2 January 2024 / Online: 2 January 2024 (10:00:17 CET)
Version 4 : Received: 4 February 2024 / Approved: 5 February 2024 / Online: 5 February 2024 (13:52:59 CET)
Version 5 : Received: 21 March 2024 / Approved: 22 March 2024 / Online: 22 March 2024 (12:06:13 CET)
Version 6 : Received: 9 May 2024 / Approved: 9 May 2024 / Online: 9 May 2024 (10:33:03 CEST)
Version 2 : Received: 5 September 2023 / Approved: 6 September 2023 / Online: 7 September 2023 (02:54:00 CEST)
Version 3 : Received: 31 December 2023 / Approved: 2 January 2024 / Online: 2 January 2024 (10:00:17 CET)
Version 4 : Received: 4 February 2024 / Approved: 5 February 2024 / Online: 5 February 2024 (13:52:59 CET)
Version 5 : Received: 21 March 2024 / Approved: 22 March 2024 / Online: 22 March 2024 (12:06:13 CET)
Version 6 : Received: 9 May 2024 / Approved: 9 May 2024 / Online: 9 May 2024 (10:33:03 CEST)
How to cite: Renteln, M. A New Paradigm in Cancer Treatment: Identifying and Targeting Clonal Mutations. Preprints 2023, 2023081536. https://doi.org/10.20944/preprints202308.1536.v5 Renteln, M. A New Paradigm in Cancer Treatment: Identifying and Targeting Clonal Mutations. Preprints 2023, 2023081536. https://doi.org/10.20944/preprints202308.1536.v5
Abstract
Over the last several years, large-scale cancer genomics studies involving multi region, multi-sample sequencing indicate that most or at least many cancer patients may have one or more “clonal" mutations in their tumors. Clonal mutations are those that are present in all of a patient’s cancer cells. They can be identified via multiregion, multisample biopsies - or circulating tumor cells/cell-free DNA. Achilles Therapeutics is currently the only company targeting patient-specific, clonal mutations. They have opted to utilize an immunotherapy approach. However, I recently devised another approach for exploiting clonal mutations called “Oncolytic Vector Replication Contingent on Omnipresent Mutation Engagement” (OVERCOME). It is based on the identification of patient-specific, clonal mutations and targeting them using a bioengineered facultative intracellular bacterium. It would be initially non-replicating, but transiently regain the ability to replicate (and also transiently become hyper-virulent) upon mutation detection via molecular switches.
Keywords
Multiregion sequencing; multisample sequencing; cell-free circulating tumor DNA; clonal mutations; Achilles Therapeutics; and OVERCOME
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment